Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naïve acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INCY
CUSIP45337C10
Phone302-498-6700
Debt
Debt-to-Equity Ratio0.01
Current Ratio3.86
Quick Ratio3.84
Price-To-Earnings
Trailing P/E Ratio109.73
Forward P/E Ratio171.29
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.54 billion
Price / Sales9.69
Cash Flow$0.8710 per share
Price / Cash80.63
Book Value$7.73 per share
Price / Book9.09
Profitability
EPS (Most Recent Fiscal Year)$0.64
Net Income$-313,140,000.00
Net Margins-10.90%
Return on Equity-0.74%
Return on Assets-0.52%
Miscellaneous
Employees1,208
Outstanding Shares211,970,000
Market Cap$14,861.16
Incyte (NASDAQ:INCY) Frequently Asked Questions
What is Incyte's stock symbol?
Incyte trades on the NASDAQ under the ticker symbol "INCY."
How were Incyte's earnings last quarter?
Incyte Co. (NASDAQ:INCY) issued its quarterly earnings data on Tuesday, May, 1st. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.08. The biopharmaceutical company had revenue of $382.28 million for the quarter, compared to analysts' expectations of $384.03 million. Incyte had a negative net margin of 10.90% and a negative return on equity of 0.74%. The business's revenue was down .5% on a year-over-year basis. During the same quarter last year, the company earned $0.14 EPS. View Incyte's Earnings History.
When is Incyte's next earnings date?
What price target have analysts set for INCY?
22 brokers have issued 1 year price objectives for Incyte's shares. Their predictions range from $70.00 to $172.00. On average, they anticipate Incyte's share price to reach $108.0617 in the next twelve months. This suggests a possible upside of 53.9% from the stock's current price. View Analyst Ratings for Incyte.
What is the consensus analysts' recommendation for Incyte?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 8 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Incyte stock?
Here are some recent quotes from research analysts about Incyte stock:
- 1. JPMorgan Chase & Co. analysts commented, "We came away from an incrementally better overall appreciation of the breadth of the company’s pipeline and potential near term commercial opportunities. Management focused on six lead product candidates in relatively later stages of development, including 1) expanded opportunities for ruxolitinib/Jakafi; 2) itacitinib in in FGFR mutated tumors; 4) INCB50465 (PI3kd) in B-cell malignancies; 5) INCMGA0012 (PD-1) in various solid tumors; 6) and topical ruxolitinib in dermatologic diseases. While INCY no longer has the “home run” potential of IDO, we thought management effectively conveyed the message that a number of potential “singles and doubles” are in the near term lineup." (6/24/2018)
- 2. According to Zacks Investment Research, "Incyte's Jakafi performance was strong in 2017 driven by patient demand. The sales guidance for 2018 was also impressive. Jakafi sales are expected to get a boost from the updated labels. Incyte expects Jakafi revenues in the range of $1.35-$1.4 billion in 2018, more than 20% growth over 2017. Meanwhile, the NDA for Olumiant was resubmitted and a potential approval will further boost the top line. Incyte’s pipeline is highly encouraging with promising immune therapies including epacadostat.. However, Incyte’s dependence on only Jakafi for growth is concerning. In addition, the recent failure of epacadostat study for the melanoma study with Keytruda was a big disappointment. Shares of the company have underperformed the industry in the last six months. Loss Estimates have narrowed ahead of the Q1 earnings results. The company has a mixed record of earnings surprises in recent quarters." (4/19/2018)
Who are some of Incyte's key competitors?
Some companies that are related to Incyte include Iqvia (IQV), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and Pieris Pharmaceuticals (PIRS).
Who are Incyte's key executives?
Incyte's management team includes the folowing people:
- Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 58)
- Mr. David W. Gryska M.B.A., MBA, Exec. VP & CFO (Age 63)
- Dr. Reid M. Huber, Exec. VP & Chief Scientific Officer (Age 46)
- Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 55)
- Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 51)
Has Incyte been receiving favorable news coverage?
News headlines about INCY stock have trended positive on Wednesday, Accern Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Incyte earned a media sentiment score of 0.36 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.64 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Incyte's major shareholders?
Incyte's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (16.30%), Manning & Napier Group LLC (2.02%), Scout Investments Inc. (0.10%), Bank of Montreal Can (0.07%), Retirement Systems of Alabama (0.04%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, David W Gryska, Eric H Siegel, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein and Vijay K Iyengar. View Institutional Ownership Trends for Incyte.
Which institutional investors are selling Incyte stock?
INCY stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Gateway Investment Advisers LLC and Bank of Montreal Can. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, David W Gryska, Eric H Siegel, Herve Hoppenot, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein and Vijay K Iyengar. View Insider Buying and Selling for Incyte.
Which institutional investors are buying Incyte stock?
INCY stock was bought by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Scout Investments Inc., State of Alaska Department of Revenue, Clinton Group Inc., Campbell & CO Investment Adviser LLC, IFM Investors Pty Ltd, Fox Run Management L.L.C. and Xact Kapitalforvaltning AB. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, Herve Hoppenot and Jean Jacques Bienaime. View Insider Buying and Selling for Incyte.
How do I buy shares of Incyte?
Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Incyte's stock price today?
One share of INCY stock can currently be purchased for approximately $70.23.
How big of a company is Incyte?
Incyte has a market capitalization of $14.86 billion and generates $1.54 billion in revenue each year. The biopharmaceutical company earns $-313,140,000.00 in net income (profit) each year or $0.64 on an earnings per share basis. Incyte employs 1,208 workers across the globe.
How can I contact Incyte?
Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]
MarketBeat Community Rating for Incyte (NASDAQ INCY)
MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe INCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
